Evidence map›Paper›PMID 31582720›Full record

ArticleCell death & disease2019

Lobaplatin promotes

Dong Li, Wu-Jie Wang, Yong-Zheng Wang, Yi-Biao Wang, Yu-Liang Li

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 43 citations in OpenAlex.

  1. Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Quercetin Alleviates All-International journal of molecular sciences · 2024
    Article
  9. Mechanistic insights intoJournal of cancer research and clinical oncology · 2024
    Article
  10. Article
  11. Article
  12. Journal of clinical and translational hepatology · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dong LiDepartment of Interventional Medicine, The Second Hospital of Shandong University, Jinan, China.
Wu-Jie WangDepartment of Interventional Medicine, The Second Hospital of Shandong University, Jinan, China.
Yong-Zheng WangDepartment of Interventional Medicine, The Second Hospital of Shandong University, Jinan, China.
Yi-Biao WangDepartment of Pediatrics, The Second Hospital of Shandong University, Jinan, China.
Yu-Liang LiDepartment of Interventional Medicine, The Second Hospital of Shandong University, Jinan, China. lyl.pro@sdu.edu.cn.
Second Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the mechanism underlying the effect of a combination treatment of

Indexed as

Activating Transcription Factor 4AnimalsApoptosisCarcinoma, HepatocellularCell ProliferationCyclobutanesDown-RegulationeIF-2 KinaseEukaryotic Initiation Factor-2Hep G2 CellsHumansIodine RadioisotopesLiver NeoplasmsMaleMice, Inbred BALB CMice, NudeActivating Transcription Factor 4CyclobutaneseIF-2 KinaseEukaryotic Initiation Factor-2Iodine RadioisotopeslobaplatinOrganoplatinum CompoundsTranscription Factor CHOP

Identifiers

PMID31582720
PMCPMC6776519
OpenAlexW2977659401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.